SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-20-004047
Filing Date
2020-04-20
Accepted
2020-04-20 08:30:33
Documents
10
Effectiveness Date
2020-04-20

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20200417xdefa14a.htm DEFA14A 70702
2 GRAPHIC tmb-20200417xdefa14ag001.gif GRAPHIC 96293
3 GRAPHIC tmb-20200417xdefa14ag002.gif GRAPHIC 171497
4 GRAPHIC tmb-20200417xdefa14ag003.gif GRAPHIC 121736
5 GRAPHIC tmb-20200417xdefa14ag004.gif GRAPHIC 131494
6 GRAPHIC tmb-20200417xdefa14ag005.gif GRAPHIC 150114
7 GRAPHIC tmb-20200417xdefa14ag006.gif GRAPHIC 176306
8 GRAPHIC tmb-20200417xdefa14ag007.gif GRAPHIC 123381
9 GRAPHIC tmb-20200417xdefa14ag008.gif GRAPHIC 121949
10 GRAPHIC tmb-20200417xdefa14ag009.gif GRAPHIC 70665
  Complete submission text file 0001558370-20-004047.txt   1675173
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: DEFA14A | Act: 34 | File No.: 001-37569 | Film No.: 20801332
SIC: 2834 Pharmaceutical Preparations